| Year |
Citation |
Score |
| 2024 |
Sala-Rabanal M, Yurtsever Z, Berry KN, McClenaghan C, Foy AJ, Hanson A, Steinberg DF, Greven JA, Kluender CE, Alexander-Brett JM, Nichols CG, Brett TJ. Modulation of TMEM16B Channel Activity by the Calcium-Activated Chloride Channel Regulator 4 (CLCA4) in Human Cells. The Journal of Biological Chemistry. 107432. PMID 38825009 DOI: 10.1016/j.jbc.2024.107432 |
0.448 |
|
| 2024 |
Efthymiou S, Scala M, Nagaraj V, Ochenkowska K, Komdeur FL, Liang RA, Abdel-Hamid MS, Sultan T, Barøy T, Van Ghelue M, Vona B, Maroofian R, Zafar F, Alkuraya FS, Zaki MS, ... ... McClenaghan C, et al. Novel loss-of-function variants expand ABCC9-related intellectual disability and myopathy syndrome. Brain : a Journal of Neurology. PMID 38217872 DOI: 10.1093/brain/awae010 |
0.365 |
|
| 2023 |
Gao J, McClenaghan CG, Matreyek K, Grange DK, Nichols CG. . The Journal of Pharmacology and Experimental Therapeutics. PMID 37527933 DOI: 10.1124/jpet.123.001659 |
0.442 |
|
| 2023 |
McClenaghan C, Mukadam MA, Roeglin J, Tryon RC, Grabner M, Dayal A, Meyer GA, Nichols CG. Skeletal muscle delimited myopathy and verapamil toxicity in SUR2 mutant mouse models of AIMS. Embo Molecular Medicine. e16883. PMID 37154692 DOI: 10.15252/emmm.202216883 |
0.434 |
|
| 2023 |
Scala R, Maqoud F, McClenaghan C, Harter TM, Perrone MG, Scilimati A, Nichols CG, Tricarico D. Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent K Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome. Cells. 12. PMID 36980269 DOI: 10.3390/cells12060928 |
0.335 |
|
| 2022 |
Gao J, McClenaghan C, Christiaans I, Alders M, van Duinen K, van Haelst MM, van Haaften G, Nichols CG. Lymphedema as first clinical presentation of Cantu Syndrome: reversed phenotyping after identification of gain-of-function variant in ABCC9. European Journal of Human Genetics : Ejhg. PMID 36336713 DOI: 10.1038/s41431-022-01210-x |
0.453 |
|
| 2022 |
McClenaghan C, Nichols CG. Kir6.1 and SUR2B and Cantú syndrome. American Journal of Physiology. Cell Physiology. PMID 35876283 DOI: 10.1152/ajpcell.00154.2022 |
0.499 |
|
| 2021 |
Singareddy SS, Roessler HI, McClenaghan C, Ikle JM, Tryon RC, van Haaften G, Nichols CG. ATP-sensitive potassium channels in zebrafish cardiac and vascular smooth muscle. The Journal of Physiology. PMID 34820842 DOI: 10.1113/JP282157 |
0.648 |
|
| 2021 |
Zhang H, Hanson AM, Scherf de Almeida TU, Emfinger CH, McClenaghan C, Harter T, Yan Z, Cooper PE, Brown GS, Arakel EC, Mecham RP, Kovacs A, Halabi CM, Schwappach B, Remedi MS, et al. Complex consequences of Cantu Syndrome SUR2 variant R1154Q in genetically modified mice. Jci Insight. PMID 33529173 DOI: 10.1172/jci.insight.145934 |
0.477 |
|
| 2020 |
Scala R, Maqoud F, Zizzo N, Mele A, Camerino GM, Zito FA, Ranieri G, McClenaghan C, Harter TM, Nichols CG, Tricarico D. Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome. Frontiers in Pharmacology. 11: 604885. PMID 33329006 DOI: 10.3389/fphar.2020.604885 |
0.462 |
|
| 2020 |
McClenaghan C, Hanson A, Lee SJ, Nichols CG. Coronavirus Proteins as Ion Channels: Current and Potential Research. Frontiers in Immunology. 11: 573339. PMID 33154751 DOI: 10.3389/fimmu.2020.573339 |
0.417 |
|
| 2020 |
McClenaghan C, Huang Y, Matkovich SJ, Kovacs A, Weinheimer CJ, Perez R, Broekelmann TJ, Harter TM, Lee JM, Remedi MS, Nichols CG. The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome. Function (Oxford, England). 1: zqaa004. PMID 32865539 DOI: 10.1093/function/zqaa004 |
0.459 |
|
| 2020 |
Maqoud F, Scala R, Mele A, McClenaghan C, Remedi MS, Nichols CC, Tricarico D. Biophysical and Pharmacological Characterization of Atp-Sensitive Potassium Channels in Mice Kir6.1WT/V65M Mirroring the Human Cantu′ Syndrome Biophysical Journal. 118. DOI: 10.1016/J.Bpj.2019.11.3195 |
0.592 |
|
| 2020 |
Singareddy SS, Roessler HI, McClenaghan C, Tryon RC, van Haaften G, Nichols CG. KATP Channels in Zebrafish Cardiovascular System: A Model to Study Cantú Syndrome Biophysical Journal. 118: 259a. DOI: 10.1016/J.Bpj.2019.11.1503 |
0.621 |
|
| 2019 |
Grange DK, Roessler HI, McClenaghan C, Duran K, Shields K, Remedi MS, Knoers NVAM, Lee JM, Kirk EP, Scurr I, Smithson SF, Singh GK, van Haelst MM, Nichols CG, van Haaften G. Cantú syndrome: Findings from 74 patients in the International Cantú Syndrome Registry. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics. 181: 658-681. PMID 31828977 DOI: 10.1002/Ajmg.C.31753 |
0.441 |
|
| 2019 |
McClenaghan C, Huang Y, Yan Z, Harter T, Halabi CM, Chalk R, Kovacs A, van Haaften G, Remedi MS, Nichols CG. Glibenclamide reverses cardiovascular abnormalities of Cantu Syndrome driven by KATP channel overactivity. The Journal of Clinical Investigation. PMID 31821173 DOI: 10.1172/Jci130571 |
0.633 |
|
| 2019 |
Smeland MF, McClenaghan C, Roessler HI, Savelberg S, Hansen GÅM, Hjellnes H, Arntzen KA, Müller KI, Dybesland AR, Harter T, Sala-Rabanal M, Emfinger CH, Huang Y, Singareddy SS, Gunn J, et al. ABCC9-related Intellectual disability Myopathy Syndrome is a K channelopathy with loss-of-function mutations in ABCC9. Nature Communications. 10: 4457. PMID 31575858 DOI: 10.1038/S41467-019-12428-7 |
0.519 |
|
| 2019 |
Ma A, Gurnasinghani S, Kirk EP, McClenaghan C, Singh GK, Grange DK, Pandit C, Zhou Y, Roscioli T, Elakis G, Buckley M, Mehta B, Roberts P, Mervis J, Biggin A, et al. Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience. American Journal of Medical Genetics. Part A. PMID 31175705 DOI: 10.1002/Ajmg.A.61200 |
0.384 |
|
| 2019 |
McClenaghan C, Woo KV, Nichols CG. Pulmonary Hypertension and ATP-Sensitive Potassium Channels. Hypertension (Dallas, Tex. : 1979). HYPERTENSIONAHA11912. PMID 31132951 DOI: 10.1161/Hypertensionaha.119.12992 |
0.51 |
|
| 2019 |
McClenaghan C, Huang Y, Halabi C, Harter T, Mecham RP, Remedi MS, Nichols CG. The Mechanism of Cardiovascular Pathophysiology in Cantu Syndrome and Response to Glibenclamide in Novel KATP Channel Mutant Mouse Models Biophysical Journal. 116: 31a. DOI: 10.1016/J.Bpj.2018.11.209 |
0.56 |
|
| 2018 |
Huang Y, McClenaghan C, Harter TM, Hinman K, Halabi CM, Matkovich SJ, Zhang H, Brown GS, Mecham RP, England SK, Kovacs A, Remedi MS, Nichols CG. Cardiovascular consequences of KATP overactivity in Cantu syndrome. Jci Insight. 3. PMID 30089727 DOI: 10.1172/Jci.Insight.121153 |
0.448 |
|
| 2018 |
McClenaghan C, Huang Y, Harter T, Brown GS, Hinman K, Halabi C, Matkovich S, Mecham RP, Weinheimer CJ, Kovacs A, England S, Remedi MS, Nichols CG. Abstract 011: Cardiovascular Consequences of Cantu Syndrome and Response to Glibenclamide Treatment in Two Novel KATP Channel Mutant Mouse Models Arteriosclerosis, Thrombosis, and Vascular Biology. 38. DOI: 10.1161/Atvb.38.Suppl_1.011 |
0.53 |
|
| 2017 |
McClenaghan C, Hanson A, Sala-Rabanal M, Roessler HI, Josifova D, Grange DK, van Haaften G, Nichols CG. Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms. The Journal of Biological Chemistry. PMID 29275331 DOI: 10.1074/Jbc.Ra117.000351 |
0.568 |
|
| 2017 |
Cooper PE, McClenaghan C, Chen X, Stary-Weinzinger A, Nichols CG. Conserved functional consequences of disease-associated mutations in the slide-helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel. The Journal of Biological Chemistry. PMID 28842488 DOI: 10.1074/Jbc.M117.804971 |
0.53 |
|
| 2017 |
Aryal P, Jarerattanachat V, Clausen MV, Schewe M, McClenaghan C, Argent L, Conrad LJ, Dong YY, Pike AC, Carpenter EP, Baukrowitz T, Sansom MS, Tucker SJ. Bilayer-Mediated Structural Transitions Control Mechanosensitivity of the TREK-2 K2P Channel. Structure (London, England : 1993). PMID 28392258 DOI: 10.1016/J.Str.2017.03.006 |
0.705 |
|
| 2016 |
McClenaghan C, Schewe M, Aryal P, Carpenter EP, Baukrowitz T, Tucker SJ. Polymodal activation of the TREK-2 K2P channel produces structurally distinct open states. The Journal of General Physiology. 147: 497-505. PMID 27241700 DOI: 10.1085/Jgp.201611601 |
0.724 |
|
| 2016 |
McClenaghan C, Schewe M, Baukrowitz T, Tucker SJ. Polymodal Gating of the TREK-2 K2P Potassium Channel Involves Structurally Distinct Open States Biophysical Journal. 110: 607. DOI: 10.1016/J.Bpj.2015.11.3241 |
0.745 |
|
| 2015 |
Dong YY, Pike AC, Mackenzie A, McClenaghan C, Aryal P, Dong L, Quigley A, Grieben M, Goubin S, Mukhopadhyay S, Ruda GF, Clausen MV, Cao L, Brennan PE, Burgess-Brown NA, et al. K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. Science (New York, N.Y.). 347: 1256-9. PMID 25766236 DOI: 10.1126/Science.1261512 |
0.736 |
|
| 2015 |
McClenaghan C, Carpenter E, Stephen TJ. Mechanisms of TREK-2 Potassium Channel Gating Biophysical Journal. 108. DOI: 10.1016/J.Bpj.2014.11.2386 |
0.655 |
|
| 2014 |
Pike A, Dong Y, Mackenzie A, McClenaghan C, Mukhopadhyay S, Burgess-Brown N, Tucker S, Carpenter E. Structures of the human two-pore domain potassium channels TREK-1 and TREK-2 Acta Crystallographica Section A. 70. DOI: 10.1107/S2053273314085106 |
0.685 |
|
| 2012 |
McClenaghan C, Zeng F, Verkuyl JM. TRPA1 agonist activity of probenecid desensitizes channel responses: consequences for screening. Assay and Drug Development Technologies. 10: 533-41. PMID 22681402 DOI: 10.1089/Adt.2012.447 |
0.396 |
|
| Show low-probability matches. |